Novartis chief executive Vas Narasimhan warns that proposed U.S. limits on biotech investments involving China could slow or disrupt drug development. In both reports, he frames the concern around practical difficulties in moving technologies and work between U.S. and Chinese operations that are needed to develop medicines.

The articles explain that the issue centers on a U.S. Treasury proposal for investment restrictions. Quartz emphasizes how curbs could hinder transferring technologies across the two countries’ operations, while Bloomberg Technology highlights the broader risk to developing new medicines. Despite differences in framing, both accounts attribute the warning to Narasimhan and connect it directly to the potential impact of U.S. biotech investment limits on Novartis’s research and development process.

Overall, the story focuses on the potential downstream effect of U.S.-China biotech investment policy on a major pharmaceutical company’s ability to develop drugs, as described by its CEO.